In focus · trending topic

ARCA biopharma

8 stories · following the connections

ARCA Biopharma announces first quarter 2018 financial results AND Provides Corporate Update

By Nasdaq OMXMay 8, 2018, 8:15 PM UTC

ARCA biopharma Announces Completion of GENETIC-AF Phase 2B Clinical Trial

By Nasdaq OMXJan 8, 2018, 1:31 PM UTC

ARCA Biopharma Announces Issuance of European Patent for Treating Cardiovascular Diseases and Conditions With a New Chemical Entity Utilizing Genetic Targeting

By Nasdaq OMXNov 16, 2017, 1:30 PM UTC

ARCA biopharma Announces Third Quarter 2017 Financial Results and Provides Business Update

By Nasdaq OMXNov 9, 2017, 9:05 PM UTC

ARCA biopharma Announces Completion of Enrollment for GENETIC-AF Phase 2B Clinical Trial

By Nasdaq OMXAug 16, 2017, 12:30 PM UTC

ARCA biopharma Announces GENETIC-AF Data and Safety Monitoring Board Recommendation to Complete Phase 2B GENETIC-AF Clinical Trial Based on Efficacy and Safety Data in Phase 2B Interim Analysis

By Nasdaq OMXAug 9, 2017, 8:30 PM UTC

ARCA biopharma Announces Second Quarter 2017 Financial Results and Provides Business Update

By Nasdaq OMXAug 3, 2017, 8:15 PM UTC

ARCA Biopharma Announces Database Lock for GENETIC-AF Phase 2B Interim Efficacy Analysis – DSMB Recommendation Anticipated in August 2017

By Nasdaq OMXJun 20, 2017, 12:30 PM UTC